|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-earning deposits and Federal Funds sold | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Securities available for sale | ||||||||||||||||||||
| Federal Home Loan Bank stock | ||||||||||||||||||||
| Mortgage loans held for sale | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Loans, net | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Core deposit intangible | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Noninterest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Securities sold under agreements to repurchase | ||||||||||||||||||||
| Federal Home Loan Bank advances | ||||||||||||||||||||
| Subordinated debentures | ||||||||||||||||||||
| Subordinated notes | ||||||||||||||||||||
| Term note | ||||||||||||||||||||
| Accrued interest and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' equity | ||||||||||||||||||||
| Preferred stock, no par value; 1,000,000 shares authorized; none issued | ||||||||||||||||||||
| Common stock, no par value; 40,000,000 shares authorized; 17,285,911 shares issued and outstanding at June 30, 2026, and 17,181,096 shares issued and outstanding at December 31, 2025 | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
